Targets › RPE65
3 programs from 3 companies in 6 trials: 4 Phase 1, 2 Phase 3; Ophthalmology; next expected readout Oct 2027.
Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore. (UniProt, Q16518)
Open in Phaseline: the race on RPE65, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Spark Therapeutics | Voretigene Neparvovec Retinoid isomerohydrolase exogenous gene | RPE65 | Phase 3 | Inherited Retinal Dystrophy Due to RPE65 Mutations; Leber Congenital Amaurosis | Oct 2027 |
| Innostellar Biotherapeutics | LX101 Gene therapy for RPE65 mutations | RPE65 | Phase 3 | Inherited Retinal Dystrophy Associated With RPE65 Mutations; Inherited Retinal Dystrophy | Dec 2027 |
| Frontera Therapeutics | FT-001 Subretinal AAV5-delivered RPE65 gene therapy | RPE65 | Phase 1 | Biallelic RPE65 Mutation-associated Retinal Dystrophy | Nov 2029 |
Inherited Retinal Dystrophy Associated With RPE65 Mutations (2) Inherited Retinal Dystrophy (1) Biallelic RPE65 Mutation-associated Retinal Dystrophy (1) Inherited Retinal Dystrophy Due to RPE65 Mutations (1) Leber Congenital Amaurosis (1)
other (3)
Innostellar Biotherapeutics (1) Frontera Therapeutics (1) Spark Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.